

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024



Prof. María-Victoria Mateos
University of Salamanca,
Spain



Dr Rakesh Popat
University College London Hospital,
UK



Prof. Evangelos Terpos
National and Kapodistrian
University of Athens, Greece

Recorded following **COMy** (23–26 May 2024, Paris, France)
and **EHA** (13–16 June 2024, Madrid, Spain)

Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities*
- *USF Health and touchIME accepts no responsibility for errors or omissions*

Approved indications for BCMA-targeting agents

Prof. María-Victoria Mateos
University of Salamanca
Spain



Recorded following **COMy** (23–26 May 2024, Paris, France)
and **EHA** (13–16 June 2024, Madrid, Spain)

P942: Long-term follow-up from the phase I/II MajesTEC-1 trial of teclistamab in patients with RRMM

Oriol A, et al.

Study population^{1,2}



Patient cohort


- Baseline characteristics previously published²
- 77.6% triple-class refractory
- Median previous lines of therapy: 5



30.4-month follow-up

- N=165, recommended phase II QW SC dose
 - n=65, transitioned to Q2W dosing
- Patients still on treatment: n=38 (n=37 on Q2W)

Outcomes



Teclistamab continues to demonstrate deep and durable responses, even with less frequent dosing. This is the longest follow-up of any bispecific antibody in RRMM.

P942: Long-term follow-up from the phase I/II MajesTEC-1 trial of teclistamab in patients with RRMM

Oriol A, et al.

Safety profile

Grade 3/4 TEAEs, %	N=165
Any	94.5
Haematologic	
Neutropenia	65.5
Anaemia	37.6
Thrombocytopenia	23.0
Lymphopenia	34.5
Leukopenia	9.1



CRS and
ICANS



Infections



Other

- CRS occurred in **72.1%** of patients (grade 3/4, 0.6%)
 - **No changes** at 30.4-month follow-up
 - Occurred in **78.8%** of patients (grade 3/4, 55.2%)
 - **18** of 22 grade 5 infections were due to COVID-19
 - No new grade 5 COVID-19 TEAEs at 30.4-month follow-up
 - Onset of new grade ≥ 3 infections generally declined over time:
 - Transitioning to Q2W dosing and increasing use of Ig replacement may contribute to this trend
- TEAEs leading to:
- dose **reduction** in **one** patient
 - **discontinuation** in **eight** patients; five due to infection
 - No new safety signals were reported

Teclistamab offers an effective treatment in RRMM with a manageable safety profile and no new safety signals.

P923: Efficacy and safety of teclistamab in patients with RRMM with high-risk features: A subgroup analysis from the phase I/II MajesTEC-1 STUDY

Costa LJ, et al.

Outcomes by patient subgroup (~30-month follow-up)

High-risk features	Proportion,% (n/N)	Response rates, %			ORR, %
Total	100.0 (165)	3.6	13.3	46.1	63.0
Penta-drug refractory	30.3 (50/165)	2.0	10.0	48.0	60.0
HR cytogenetics	25.7 (38/148)	2.6	15.8	42.1	60.5
Age ≥75 years	14.5 (24/165)	4.2	8.3	41.7	54.2
BMPCs ≥60%	11.2 (18/160)		16.7	27.8	44.4
Extramedullary disease	17.0 (28/165)	7.1	10.7	17.9	35.7
ISS stage III	12.3 (20/162)	5.0	15.0	15.0	35.0



Safety profiles, including grade 3/4 TEAEs and rates of discontinuation and deaths due to AEs, were generally comparable between HR subgroups and the overall population receiving the RP2D


Teclistamab can provide clinical benefit to patients with some HR features historically associated with poorer outcomes. HR subgroups with lower ORRs may benefit from earlier treatment when fewer HR features are present or treating with combinations to enhance antimyeloma activity.

AE, adverse event; BMPC, bone marrow plasma cells; CR, complete response; HR, high risk; ISS, International Staging System; ORR, overall response rate; PR, partial response; RP2D, recommended phase 2 dose; RRMM, relapsed/refractory multiple myeloma; TEAE, treatment-emergent AE; VGPR, very good partial response.
Costa LJ, et al. Presented at EHA2024, Madrid, Spain, 13–16 June 2024. Abstr. P943.

P932: MagnetisMM-3: Long-term survival after elranatamab monotherapy in patients with RRMM

Mohty M, et al.

Baseline characteristics and treatment schedule

 Refractory to ≥ 1 PI, ≥ 1 IMiD, and ≥ 1 anti-CD38 antibody	BCMA-naive (N=123)
Median age, years (range)	68.0 (36–89)
Median prior lines of therapy, n (range)	5.0 (2–22)
Prior stem cell transplant, %	70.7
Triple-class exposed/refractory, %	100/96.7
Penta-class exposed/refractory, %	70.7/42.3
Extramedullary disease, %	31.7
R-ISS III, %	15.4
High-risk cytogenetics, %	25.2
Refractory to last line of therapy, %	95.9

Treatment schedule

Patients received SC elranatamab as 2 step-up priming doses followed by 76 mg QW

Patients with ≥ 6 months of QW dosing achieving $\geq PR$ for ≥ 2 months were transitioned to


Q2W dosing schedule and to a Q4W dosing schedule after ≥ 6 Q2W cycles

P932: MagnetisMM-3: Long-term survival after elranatamab monotherapy in patients with RRMM


Mohty M, et al.

Efficacy and safety outcomes

ORR per BICR



24-month rates for \geq CR



mPFS 17.2 months (9.8–NE)

mOS 24.6 months (13.4–NE)



No new safety signals were observed with extended follow-up

With an additional 6 months' follow-up:

- **Four new deaths** had occurred
 - Two patients with **disease under study**
 - One patient each with **unknown reason** and **septic shock**
- **Five patients** had **secondary primary malignancies (SPMs)**
 - All were cutaneous squamous cell carcinoma
 - All received prior lenalidomide and a stem cell transplant
 - No haematological SPMs were observed

Elranatamab continued to demonstrate deep and durable responses in heavily pretreated BCMA-naive patients with RRMM, with no new safety signals observed with extended follow-up.

P959: CARTITUDE-4 subgroup analysis: Ciltacabtagene autoleucel (cilta-cel) vs SOC in patients with functionally high-risk (fHR) MM

Weisel K, et al.

Baseline characteristics



- Adults with MM and ECOG PS ≤ 1
- 1–3 prior LOT including PI + IMiD
- Lenalidomide refractory
- No prior CAR T or anti-BCMA

	1 prior LOT		1 prior LOT + fHR	
	Cilta-cel (n=68)	SOC (n=68)	Cilta-cel (n=40)	SOC (n=39)
Median age, years (range)	60.5 (27–78)	60.0 (35–78)	60.0 (27–71)	60.0 (40–78)
ISS stage II/III, %	29.4	32.4	30.0	35.9
High-risk cytogenetics*, %	57.4	66.2	55.0	69.2
With ≥ 2 high-risk abnormalities	29.4	29.4	32.5	30.8
Prior ASCT, %	82.4	88.2	82.5	84.6
Prior anti-CD38 antibody, %	2.9	4.4	5.0	2.6
High tumour burden, %	13.2	11.8	12.5	10.3
Soft tissue plasmacytoma, %	17.6	10.3	15.0	10.3

*High-risk cytogenetics defined as any of the following cytogenetic features: del17p, t(14;16), t(4;14), or gain/amp(1q).

ASCT, autologous stem cell transplant; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; ECOG PS, Eastern Cooperative Oncology Group Performance Status; fHR, functionally high risk; IMiD, immunomodulatory drug; ISS, International Staging System; LOT, line of therapy; MM, multiple myeloma; PI, proteasome inhibitor; SOC, standard of care.


Weisel K, et al. Presented at EHA2024, Madrid, Spain, 13–16 June 2024. Abstr. P959.

P959: CARTITUDE-4 subgroup analysis: Ciltacabtagene autoleucel (cilta-cel) vs SOC in patients with functionally high-risk (fHR) MM


Weisel K, et al.

Efficacy outcomes

PFS and MRD-negativity



ORR




Regardless of functional risk strata, after 1 prior line of therapy, a single cilta-cel infusion substantially improved PFS and depth of response vs SOC in lenalidomide-refractory patients with MM.

P959: CARTITUDE-4 subgroup analysis: Ciltacabtagene autoleucel (cilta-cel) vs SOC in patients with functionally high-risk (fHR) MM

Weisel K, et al.

Safety profile



AEs were generally similar in patients with 1 prior LOT and those with 1 prior LOT and functionally high-risk MM.

P978: Phase III CARTITUDE-4 analysis by cytogenetic risk: Ciltacabtagene autoleucel (cilta-cel) vs standard of care in lenalidomide-refractory MM

Mina R, et al.

Baseline characteristics and cytogenetic status




- Adults with MM and ECOG PS ≤1
- 1–3 prior lines including PI + IMiD
- Lenalidomide refractory
- No prior CAR T or anti-BCMA

15.9 months median follow-up

High-risk

	Cilta-cel (n=123)	SOC (n=132)
Median age, years (range)	62 (40–78)	62 (35–80)
Time since diagnosis, years (range)	3.2 (0.5–12.1)	3.4 (0.5–13.2)
Median prior lines of therapy, %		
1	31.7	34.1
2–3	68.3	65.9
Prior ASCT, %	84.6	90.9
Triple-class exposed, %	26.8	25.8
Soft tissue plasmacytomas, %	22.0	15.2


High-risk cytogenetics status



P978: Phase III CARTITUDE-4 analysis by cytogenetic risk: Ciltacabtagene autoleucel (cilta-cel) vs standard of care in lenalidomide-refractory MM

Mina R, et al.

Efficacy outcomes by cytogenetic risk*



Cilta-cel demonstrated favourable efficacy outcomes vs SOC in patients with high-risk and standard-risk cytogenetics.

*High-risk cytogenetic abnormalities, including t(4;14), del(17p), t(14;16), and gain/amp(1q).

CR, complete response; MM, multiple myeloma; MRD, minimal residual disease ($\times 10^{-5}$); NE, not evaluable; ORR, objective response rate; PFS, progression free survival; SOC, standard of care.

Mina R, et al. Presented at EHA2024, Madrid, Spain, 13–16 June 2024. Abstr. P978.

P978: Phase III CARTITUDE-4 analysis by cytogenetic risk: Ciltacabtagene autoleucel (cilta-cel) vs standard of care in lenalidomide-refractory MM

Mina R, et al.

mPFS by cytogenetic status and abnormalities

Cilta-cel high-risk (n=123)

SOC high-risk (n=132)

High-risk cytogenetics*



Cilta-cel lessens the impact of high-risk cytogenetics on PFS, and improved PFS compared with SOC.

*High-risk cytogenetic abnormalities, including t(4;14), del(17p), t(14;16), and gain/amp(1q).

CI, confidence interval; HR, hazard ratio; m, median; MM, multiple myeloma; NE, not evaluable; PFS, progression-free survival; SOC, standard of care.

Mina R, et al. Presented at EHA2024, Madrid, Spain, 13–16 June 2024. Abstr. P978.

New approaches to the use of existing BCMA-targeting agents

Prof. María-Victoria Mateos
University of Salamanca
Spain



Recorded following **COMy** (23–26 May 2024, Paris, France)
and **EHA** (13–16 June 2024, Madrid, Spain)

LB3440: Phase III DREAMM-8 trial: Belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs PVd in RRMM

Dimopoulos MA, et al.

Baseline characteristics and treatment status



- Adults with MM
- Anti-BCMA and pomalidomide naive
- ≥1 prior line including lenalidomide
- PD on/after latest therapy
- Not refractory/intolerant to bortezomib

21.8 months' median follow-up
(0.03–39.23)

	Randomized (N=302)	
	BPd (ITT n=155)	PVd (ITT n=147)
Age, years (range)	67 (40–82)	68 (34–86)
Time since diagnosis, years (range)	4.04 (0.4–16.7)	3.43 (0.4–17.7)
Time to relapse after 1L therapy initiation, %		
≤12 months	14	14
>12 months	86	86
Extramedullary disease, %	13	7
PI exposed/refractory, %	90/26	93/24
Lenalidomide exposed/refractory, %	100/81	100/76
Anti-CD38 mAb exposed/refractory, %	25/23	29/24
Ongoing treatment	36%	21%

LB3440: Phase III DREAMM-8 trial: Belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs PVd in RRMM

Dimopoulos MA, et al.

Primary endpoint and key secondary endpoints



HR 0.52

(95% CI 0.37–0.73); $p < 0.001$

PFS benefit seen consistently across all prespecified subgroups



Ongoing response (% patients) **55% vs 31%**



Median OS was NR in both arms (HR 0.77; 95% CI 0.53–1.14)



Favourable survival outcomes and treatment response with BPd vs PVd; additional OS follow-up is ongoing.

*Percentage of total ITT patients who were MRD negative by NGS based on sensitivity of 10^{-5} . Data shown for patients with complete response or better.

B, belantamab mafodotin; CI, confidence interval; d, dexamethasone; DOR, duration of response; HR, hazard ratio; ITT, intent-to-treat; m, median; MRD, minimal residual disease; NGS, next-generation sequencing; NR, not reached; OS, overall survival; P, pomalidomide; PFS, progression-free survival; RRMM, relapsed/refractory multiple myeloma; V, bortezomib. Dimopoulos MA, et al. Presented at EHA2024, Madrid, Spain (June 13–16). Abstract: LB3440.

LB3440: Phase III DREAMM-8 trial: Belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs PVd in RRMM

Dimopoulos MA, et al.

Safety profile

Grade 3/4 AEs, %	BPd (n=150)	PVd (n=145)
Any	91	73
Neutropenia	57	39
Infections (grade ≥3)	49	26
Thrombocytopenia	38	29
Any ocular AESI	43	2
Blurred vision	17	0
Dry eye	8	0



Bilateral BCVA worsening in patients with normal baseline (20/25 or better in ≥1 eye)

BPd	20/50 or worse	20/200 or worse
Patients, %	34	1
Median time to first event, days (range)	112 (28–761)	351 (29–673)
First event resolved to normal baseline, %	84	50

Management of ocular AEs

83% dose holds and 59% reduced dosing frequency

9% discontinuation rate

Safety profile broadly consistent with known profiles of individual regimen components. Visual acuity changes that could affect daily living were reversible in most BPd-treated patients.

S214: Phase III DREAMM-7 trial: Belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs DVd in RRMM


Mateos MV, et al.

Baseline characteristics and treatment status

- Anti-BCMA-naive adults with MM
- ≥1 prior line of therapy
- PD on/after latest therapy
- Not refractory/intolerant to bortezomib or daratumumab


	Randomized (N=494)	
	BVd ITT n=243 (treated, n=242)	DVd ITT n=251 (treated, n=246)
Age, years (range)	65 (34–86)	64 (32–89)
1 prior line of therapy, %	51	50
≥2 prior lines of therapy, %	48	50
Prior bortezomib, %	86	84
Prior lenalidomide, %	52	52
Lenalidomide refractory, %	33	35
Prior daratumumab, %	1	2
28.2 months median follow-up (0.1–40.0)	Ongoing treatment	
	33%	20%

Belantamab mafodotin discontinued (n=161)



- Progressive disease: 24%
- AE: 19%
- Physician decision: 14%
- Patient withdrawal: 9%
- Loss to follow up: <1%
- Protocol-defined stopping criteria reached: <1%

Daratumumab discontinued (n=195)



- Progressive disease: 59%
- AE: 9%
- Patient withdrawal: 5%
- Physician decision: 4%
- Loss to follow up: <1%
- Protocol deviation: <1%

AE, adverse event; B, belantamab mafodotin; BCMA, B cell maturation antigen; D, daratumumab; d, dexamethasone; ITT, intent-to-treat; PD, progressive disease; P, pomalidomide; RRMM, relapsed/refractory multiple myeloma; V, bortezomib. Mateos MV, et al. Presented at EHA2024, Madrid, Spain (June 13–16). Abstract: S214.

S214: Phase III DREAMM-7 trial: Belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs DVd in RRMM

Mateos MV, et al.

Primary endpoint and key secondary endpoints



HR 0.41

(95% CI 0.31–0.53); p<0.00001

PFS benefit seen consistently across all prespecified subgroups



Ongoing response (% patients) **53%** vs **29%**



Median OS was NR in both arms (HR 0.57; 95% CI 0.4–0.8; p=0.00049*)

Favourable survival outcomes and treatment response with BVd vs DVd; additional OS follow-up is ongoing.

*The P value has not yet reached criteria for statistical significance (p<0.00037) at interim analysis. †MRD negativity rate defined as percentage of patients who were MRD negative by NGS based on a sensitivity of 10⁻⁵. B, belantamab mafodotin; CI, confidence interval; D, daratumumab; d, dexamethasone; DOR, duration of response; HR, hazard ratio; m, median; MRD, minimal residual disease; NR, not reached; OS, overall survival; PFS, progression-free survival; RRMM, relapsed/refractory multiple myeloma; V, bortezomib. Mateos MV, et al. Presented at EHA2024, Madrid, Spain (June 13–16). Abstract: S214.

S214: Phase III DREAMM-7 trial: Belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs DVd in RRMM

Mateos MV, et al.

Safety profile

AEs (% patients)	BVd (N=242)	DVd (N=246)
Any grade 3/4	95	76
Leading to dose reduction	75	59
Leading to dose interruption/delay	94	75
Leading to discontinuation	31	19



Bilateral BCVA worsening in patients with normal baseline (20/25 or better in ≥ 1 eye)

BVd	20/50 or worse	20/200 or worse
Patients, %	34	2
Median time to first event, days (range)	73.5 (16–753)	105 (47–304)
First event resolved to normal baseline, % (n/N)	94 (77/82)	80 (4/5)

In BVd-treated patients with ocular events, 44% had dose reductions; 78% had dose delays/interruptions > 9% discontinuation rate

Safety profile broadly consistent with known profiles of individual regimen components. Among all BVd-treated patients, ocular AEs led to low treatment discontinuations.

Phase III DREAMM-7 trial — additional analyses

P938: Subgroup analyses; Mateos MV, et al.

P945: PRO analyses; Hungria V, et al.

Efficacy in subgroups¹

- Refractory to prior lenalidomide
- ≥1 high-risk cytogenetic abnormality

LEN-refractory
(n= 79; n=87)

High-risk cytogenetics
(n=67; n=69)



mPFS
(months)



HR 0.31
(95% CI 0.19–0.48)

HR 0.31
(95% CI 0.18–0.52)

ORR



PROs²

- QoL, vision and functioning measures



N=494

BVd=243

DVd=251

>90% adherence to PRO assessments

PROs were stable over time and consistent between treatment arms, e.g.

- Global health/QoL assessments
- Role/physical functioning
- Fatigue
- Pain
- Eye-related side effects manageable with dose and schedule changes
- In patients with clinically meaningful deterioration in vision-related function, overall QoL comparable to that in all patients receiving DVd



B, belantamab mafodotin; CI, confidence interval; D, daratumumab; d, dexamethasone; HR, hazard ratio; LEN, lenalidomide; mPFS, median progression-free survival; ORR, objective response rate; PRO, patient-reported outcomes; QoL, quality of life; V, bortezomib.

1. Mateos MV, et al. Presented at EHA2024, Madrid, Spain (June 13–16). Abstract: P938; 2. Hungria V, et al. Presented at EHA2024, Madrid, Spain (June 13–16). Abstract: P945.

S205: CARTITUDE-2 trial Cohort D: Ciltacabtagene autoleucel (cilta-cel) ± LEN maintenance in newly diagnosed MM with suboptimal response to frontline ASCT

Roeloffzen W, et al.

Baseline characteristics and LEN maintenance status



- History of 4–8 cycles of initial therapy including induction, high-dose ChT and ASCT ± consolidation
- Overall best response <CR

22.4 months
median
follow-up
(4.7–39.3)

N=17

10 mg daily LEN
maintenance
n=12

Age, years (range)	54 (37–69)	Time to LEN initiation, days (range)	51 (21–214)
Time from initial diagnosis to enrolment, years (range)	0.9 (0.6–1.4)	Median duration, days (range)	426.5 (70–716)
Prior PI and IMiD, %	100	Median cycles (range)	15 (3–26)
Prior anti-CD38 mAb, %	17.6	Median overall relative dose intensity (range)	93.4 (68–100)
High-risk cytogenetics, %	5.9		

S205: CARTITUDE-2 trial Cohort D: Ciltacabtagene autoleucel (cilta-cel) ± LEN maintenance in newly diagnosed MM with suboptimal response to frontline ASCT

Roeloffzen W, et al.

Key safety and efficacy outcomes

ORR: 94.1%



sCR: 88.2%

CR: 5.9%

18-month
DOR rate

93.3%
(95% CI 61.3–99.0)

18-month
PFS rate

93.8%
(95% CI 63.2–99.1)

18-month
OS rate

93.8%
(95% CI 63.2–99.1)



Select TEAEs	Grade 3/4, %
Any	100
Neutropenia	82.4
Lymphopenia	58.8
Leukopenia	35.3
Infections	29.4
Thrombocytopenia	23.5

No cases of MNT/
parkinsonism were observed

One patient with ICANS,
which resolved; six patients
with other neurotoxicities
(mostly grade 1/2)

No grade 3/4 CRS
(82.4% grade 1/2)

Cilta-cel ± LEN maintenance is promising in patients with poor response to frontline ASCT, especially given the historically poorer clinical outcomes in this population.

S208: KarMMa-2 trial Cohort 2b: Idecabtagene vicleucel (ide-cel) in clinical high-risk early relapse MM without frontline ASCT

Leleu X, et al.

Baseline characteristics and frontline and/or bridging therapy status



- Early relapse (PD <18 months from frontline therapy without ASCT)
- Frontline therapy included PI, IMiD and dexamethasone
- Measurable disease
- ECOG PS ≤1

30.1 months median follow-up
(1.0–51.4)

Treated (n=31)


Age, years (range)	60 (32–77)
Median time to progression on frontline tx, months (range)	7.1 (1.7–16.5)
High tumour burden, %	45.2
High-risk cytogenetics, %	38.7
Extramedullary disease, %	12.9
Double-class refractory, %	67.7
Triple-class refractory, %	16.1

Frontline therapy (%)

Treated (n=31)

VRd/VTd	38.7
KRd	9.7
Ixad	3.2
Rd	3.2
DRd	3.2
Other	41.9

Bridging therapy





Regimen type

- Bortezomib: 25.9%
- Carfilzomib: 44.4%
- Daratumumab: 11.1%
- Other: 18.5%

S208: KarMMa-2 trial Cohort 2b: Idecabtagene vicleucel (ide-cel) in clinical high-risk early relapse MM without frontline ASCT

Leleu X, et al.

Key efficacy outcomes



DOR rate at 24 months

With response

65.3% n = 29

With ≥CR

75.7% n = 22

Median DOR was not reached

Survival rates at 12 and 24 months (n=31)

PFS

12 months

70.0%

24 months

63.3%

Median PFS was not reached

OS

12 months

89.9%

24 months

78.9%

Median OS was not reached

ASCT, autologous stem cell transplant; CR, complete response; CRR, CR rate; DOR, duration of response; MM, multiple myeloma; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; tx, treatment. Leleu X, et al. Presented at EHA2024, Madrid, Spain (June 13–16). Abstract: S208.

S208: KarMMa-2 trial Cohort 2b: Idecabtagene vicleucel (ide-cel) in clinical high-risk early relapse MM without frontline ASCT

Leleu X, et al.

Safety profile

Grade ≥3 AEs, %	n=31
Any AE	93.5
Haematologic AEs	
Neutropenia	93.5
Anaemia	54.8
Lymphopenia	45.2
Leukopenia	38.7
Thrombocytopenia	35.5

- Grade 3/4 infection and infestations occurred in 19.4% of patients

CRS	n=31
Grade 1/2	83.9%
Median time to onset, days (range)	1.0 (1–9)
Median duration, days (range)	3.0 (1–16)
iiNT	n=31
Grade 1/2	9.7%
Median time to onset, days (range)	2.0 (1–16)
Median duration, days (range)	6.0 (1–11)

94.4% of CRS events were managed with tocilizumab

Events were managed with:

- Tocilizumab (33.3%)
- Steroids (33.3%)
- Anakinra (33.3%)



No grade 3/4 CRS or iiNT events were observed

Ide-cel showed a favourable risk–benefit profile in clinical high-risk patients with MM who experienced relapse on frontline therapy (excluding ASCT), highlighting potential use in earlier lines of therapy

Emerging BCMA-targeting agents

Prof. María-Victoria Mateos
University of Salamanca
Spain



Recorded following **COMy** (23–26 May 2024, Paris, France)
and **EHA** (13–16 June 2024, Madrid, Spain)

COMy Oral: LINKER-MM1 trial: Efficacy and safety of 200 mg linvoseltamab – a CD3 x BCMA bispecific antibody – in RRMM, including difficult-to-treat subgroups

Jagannath S, et al.

Baseline characteristics and treatment schedule



- Active MM that progressed on/after ≥ 3 lines of therapy including a PI, IMiD and anti-CD38 antibody
- Double- or triple-class refractory

11.1 months
median follow-up

200 mg
(N=117)

Patient characteristics

Median age, years (range)	70 (37–91)
Extramedullary plasmacytomas per IRC, %	16.2
Prior autologous transplant, %	65.0
Number of prior lines, median (range)	5 (2–16)
At least triple-class exposed/refractory, %	100/82.1
Refractory to last line of therapy, %	85.5
High-risk cytogenetics, %	39.3
ISS stage I–II, %	76.9
ISS stage III, %	17.9

IV dosing: Phase II expansion cohort

Weeks 1–2
Step-up doses

5 mg → Day 1
25 mg → Day 8



Weeks 3–14
200 mg

Once a week

Weeks 16–23
200 mg

Every 2 weeks

Week 24 onward
200 mg

\geq VGPR → every 4 weeks
< VGPR → every 2 weeks



Primary

- Ph 1: Safety
- Ph 2: ORR by IRC

Secondary


- Ph 1: ORR
- Ph 2: Safety, DOR, PFS, OS

COMy Oral: LINKER-MM1 trial: Efficacy and safety of 200 mg linvoseltamab – a CD3 x BCMA bispecific antibody – in RRMM, including difficult-to-treat subgroups


Jagannath S, et al.

Results

IRC-assessed ORR



Median time to response




Responses continued to deepen after switch to once every 4 weeks dosing: 48% (n/N=14/29) in VGPR achieved ≥CR after dosing switch

Response by cytogenetics



Estimated probability at 12 months of:



COMy Oral: LINKER-MM1 trial: Efficacy and safety of 200 mg linvoseltamab – a CD3 x BCMA bispecific antibody – in RRMM, including difficult-to-treat subgroups

Jagannath S, et al.

Safety profile

Grade 3/4 TEAEs, %	N=117
Any	72.6
Haematologic	
Neutropenia	40.2
Anaemia	30.8
Non-haematologic	
COVID-19	8.5
Hypokalaemia	3.4
Diarrhoea	1.7
CRS	0.9
Headache	0.9

Median exposure to treatment (200 mg): **47.4 weeks**



CRS

- Occurred in **46.2%** of patients (any grade)



ICANS

- Occurred in **7.7%** of patients
- All events concurrent with CRS or immune-related reactions



Infections

- Occurred in **73%** of patients
- Grade 3/4 in **34%** of patients



TEAEs

- Six patients experienced TEAEs leading to death within 30 days of the last treatment doses:
 - Five due to infection
 - One due to renal failure

Linvoseltamab demonstrated high efficacy in late-stage RRMM, including in pre-specified high-risk subgroups, and with an acceptable safety profile.

BCMA, B-cell maturation antigen; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; RRMM, relapsed/refractory multiple myeloma; TEAE, treatment emergent adverse event.

Jagannath S, et al. Presented at COMy, Paris, France, 23–26 May 2024. Available On-Demand at: <https://comylive.cme-congresses.com/> (accessed 06 August 2024).

S211: Efficacy, safety and recommended phase II dose finding for the BCMA bispecific antibody ABBV-383 in RRMM

Weisel K, et al.

Baseline characteristics



- Adult patients with RRMM who received ≥ 3 prior lines of therapy
- Prior exposure to PI, IMiD and anti-CD38 mAb
- ECOG PS 0–2
- No prior BCMA-targeted therapy

12.1 months
median
follow-up
(0.8–13.0)

Q4W 60 mg
(n=21)

Median age, years (range)	67 (51–87)
Median prior lines of therapy, (range)	4 (3–23)
Extramedullary disease, %	19
Triple-class refractory, %	81
Penta-class refractory, %	38
Treatment ongoing	48%



Primary reason for treatment discontinuation

29%

Disease progression

14%

DLT/TEAE

10%

Withdrawal of consent



Deaths following last dose:

- Two patients died within 30 days
- Two patients died within 90 days

S211: Efficacy, safety and recommended phase II dose finding for the BCMA bispecific antibody ABBV-383 in RRMM

Weisel K, et al.

Efficacy



Median DOR: months (95% CI)

- PR or better (n=13): **NR** (4.6–NR)
- CR or better (n=6): **NR** (NR–NR)

Survival outcomes

	Q4W 60 mg (n=21)
mPFS, months (95% CI)	NR (2.8–NR)
PFS at 12 months, % (95% CI)	54.8 (30.5–73.2)


S211: Efficacy, safety and recommended phase II dose finding for the BCMA bispecific antibody ABBV-383 in RRMM

Weisel K, et al.

Safety profile

Grade 3/4 TEAEs, %	Q4W 60 mg (n=21)
Any	86
Haematologic	
Lymphopenia	43
Neutropenia	29
Anaemia	29
Thrombocytopenia	19

No non-haematologic grade 3/4 TEAEs



- CRS onset typically occurred on the same day following first dose
- Quick recovery with standard care
- Most events were grade 1 and did not recur



ICANS

- One patient experienced grade 2 ICANS
- No other ICANS events reported

Optimal dose of Q4W 60 mg ABBV-383 monotherapy was selected on the basis of safety and efficacy, resulting in deep, durable responses.

S207: ≥1 year follow-up phase I data: Anitocabtagene autoleucel (anito-cel) in RRMM

Frigault M, et al.

Baseline characteristics



- Received ≥3 prior lines of therapy or triple-refractory
- Prior PI, IMiD and CD38-targeted therapy

26.5 months
median
follow-up
(14–44)

All
(N=38)

Median age, years (range)	66 (44–76)
Median prior lines of therapy, (range)	4 (3–16)
Extramedullary disease, %	34
High-risk cytogenetics, %	29
Triple refractory, %	100
Penta refractory, %	68

Bridging
therapy

68%

Prior
ASCT

76%



anito-cel

Dose Level 1
100 x 10⁶ CAR T cells

n=32

Dose escalation, n=6
Expansion cohort, n=26

Dose Level 2
300 x 10⁶ CAR T cells


n=6

S207: ≥1 year follow-up phase I data: Anitocabtagene autoleucel (anito-cel) in RRMM


Frigault M, et al.

Efficacy outcomes (N=38)

Best overall response



PFS rate at 24 months



- **sCR/CR rates** >80% in all sub-groups including high-risk (EMD, high-risk cytogenetics, age ≥65 years)
- 89% of MRD evaluable patients (n=25/28) MRD negative
- **Median PFS, DOR and OS** not reached at 2 years of follow-up (median 26.5 months)
- Similar deep and durable efficacy observed in high-risk patient sub-groups

S207: ≥1 year follow-up phase I data: Anitocabtagene autoleucel (anito-cel) in RRMM

Frigault M, et al.

Safety profile

Grade 3/4
haematologic AEs
≥5% after cell infusion, %

	N=38
Neutropenia	81.6
Anaemia	57.9
Thrombocytopenia	42.1
Lymphopenia	39.5
Leukopenia	18.4
Febrile neutropenia	13.2

Non haematologic AEs (non-CRS/ICANS) all ≤7.9%



- Dose level 1: Occurred in **0** patients
- Dose level 2: Occurred in **1** patient



- Dose level 1: Occurred in **1** patient
- Dose level 2: Occurred in **1** patient



During follow-up period:

- No delayed neurotoxicities
- No Guillan–Barré syndrome
- No cranial nerve palsies
- No parkinsonian-like syndromes

Anito-cel showed efficacy even in high-risk subgroups, and with a manageable safety profile
A phase II study (iMMagine-1) is now enrolling.

Dose level 1: 100 x 10⁶ CAR T cells (n=32); dose level 2 300 x 10⁶ CAR T cells (n=6).

AE, adverse events; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; RRMM, relapsed/refractory multiple myeloma.

Frigault M, et al. Presented at EHA2024, Madrid, Spain, 13–16 June 2024. Abstr. S207.

S206: FUMANBA-2: Equecabtagene autoleucel (eque-cel) in high-risk newly diagnosed MM

Chen L, et al.

Baseline characteristics and cytogenetic status





- Adults with newly diagnosed MM
- Ineligible for ASCT
- ECOG PS 0–1
- High-risk features (R-ISS stage III; mSMART 3.0 criteria)

13.1 months
median
follow-up

All
(N=16)

Median age, years (range)	58.5 (51–69)
Extramedullary disease, %	25
R-ISS Stage II, %	62.5
R-ISS Stage III, %	37.5
High-risk cytogenetics, %	100
Double-hit and R-ISS III, %	6.3
Triple-hit and R-ISS III, %	6.3




High-risk cytogenetics status



S206: FUMANBA-2: Equecabtagene autoleucel (eque-cel) in high-risk newly diagnosed MM

Chen L, et al.

Efficacy outcomes (N=16)



sCR rates similar in patients with high-risk features:

- EMD: 100% (n=4)
- R-ISS stage III: 83.3% (n=6)
- Double/triple-hit: 100% (n=10)

S206: FUMANBA-2: Equecabtagene autoleucel (eque-cel) in high-risk newly diagnosed MM

Chen L, et al.

Safety profile

Grade ≥3 TRAEs, %	N=16
Any TRAE	100
Haematologic	
Neutropenia	81.3
Lymphocytopenia	68.8
Leukopenia	62.5
Infections	
Pneumonia	18.8
COVID-19 pneumonia	6.3
Hepatitis B	6.3

No grade ≥3 CRS and no ICANS or neurotoxicity were observed



CRS

- Any grade: **11** (68.8%) patients
- Grade 1: **8** (50.0%) patients
- Grade 2: **3** (18.8%) patients
- Median time of onset: **7 days**
- Median duration: **3 days**



Other

- No extra safety signals observed
- One death due to COVID-19 infection; not attributed to eque-cel

Eque-cel showed efficacy and favourable safety in transplant-ineligible subjects with high-risk newly diagnosed MM